Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands

AIM: This study explores clinical outcome in cytochrome P450 2C19 (CYP2C19)-related poor metaboliser patients treated with either clopidogrel or prasugrel after percutaneous coronary intervention (PCI) and investigates whether this could be cost-effective. METHODS AND RESULTS: This single-centre, ob...

Descripción completa

Detalles Bibliográficos
Autores principales: Deiman, B. A. L. M., Tonino, P. A. L., Kouhestani, K., Schrover, C. E. M., Scharnhorst, V., Dekker, L. R. C., Pijls, N. H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bohn Stafleu van Loghum 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039130/
https://www.ncbi.nlm.nih.gov/pubmed/27573042
http://dx.doi.org/10.1007/s12471-016-0873-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039130/
https://www.ncbi.nlm.nih.gov/pubmed/27573042
http://dx.doi.org/10.1007/s12471-016-0873-z

Ejemplares similares